[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
August 1, 2001

Atorvastatin for Acute Coronary Syndromes

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(5):532-535. doi:10.1001/jama.286.5.532

To the Editor: The results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study reported by Dr Schwartz and colleagues1 show that data on statins in acute coronary syndromes (ACS) need careful interpretation. Results of the MIRACL study showed no benefit on clinical end points (ie, death, nonfatal myocardial infarction, and cardiac arrest) but did show a reduction in symptomatic ischemic episodes requiring hospitalization. These results likely overstate the benefits of statin therapy, as patients who underwent percutaneous coronary intervention (PCI) during the trial period were excluded from the primary combined end point.

First Page Preview View Large
First page PDF preview
First page PDF preview
×